In This Issue

Accreditation Statistics

As of August 1, 2023

Cellular Therapy Entities

  • Accredited: 255
  • Applicants: 26

Cord Blood Banks

  • Accredited: 53
  • Applicants: 9

Congratulations to the following organizations for achieving initial accreditation:

Pennsylvania Hospital, Penn Medicine: Adult autologous hematopoietic progenitor cellular therapy, peripheral blood cellular therapy product collection, and cellular therapy product processing with minimal manipulation

Sarah Cannon Transplant & Cellular Therapy Program at MountainView Hospital: Adult autologous hematopoietic progenitor cellular therapy, immune effector cellular therapy administration, peripheral blood cellular therapy product collection, and cellular therapy product processing with minimal manipulation

A complete list of accredited organizations can be found at www.factglobal.org.

Updated Donor History Questionnaires Now Available

Posted in :: 2019 Volume 7 :: Monday, July 29th, 2019

The hematopoietic progenitor cell (HPC), Apheresis and HPC, Marrow Donor History Questionnaire (DHQ) materials were developed by the AABB Interorganizational Uniform Donor History – HPC Task Force to provide establishments with a standardized tool to screen allogeneic HPC donors for communicable disease risk factors in accordance with requirements of the Food and Drug Administration (FDA), AABB, the Foundation for the Accreditation of Cellular Therapy (FACT), and the National Marrow Donor Program (NMDP).

HPC, Apheresis and HPC, Marrow DHQ Version 2.0, June 2019
The HPC, Apheresis and HPC, Marrow Donor History Questionnaire materials have been updated to version 2.0. A complete summary of the updates incorporated in this new version is in the chart detailing the changes from version 1.9.

The HPC, Cord Blood DHQ materials were developed by an AABB interorganizational Uniform Donor History – HPC task force to provide establishments with a standardized tool to screen allogeneic as well as related cord blood (HPC, Cord Blood) donors for communicable disease risk factors in accordance with requirements of the Food and Drug Administration (FDA), AABB, Foundation for the Accreditation of Cellular Therapy (FACT), and the National Marrow Donor Program. Allogeneic donors are usually collected at public cord blood banks for use by the general public. Private cord blood banks generally collect related donors for either allogeneic use in a first or second degree relative, or for autologous use. Allogeneic and related cord blood donors are screened for the same risk factors; however, the regulations for using related units allow much more flexibility for distributing the cord blood units for transplantation.

HPC, Cord Blood DHQ Version 1.7, June 2019
The HPC, Cord Donor History Questionnaire materials have been updated to version 1.7. The changes update some FDA guidance document names, dates, and/or website links, located within the DHQ, to the current version. A complete summary of the updates incorporated in this new version is in the chart detailing the changes from version 1.6.